Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease

Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):124-34. doi: 10.1007/s00259-007-0558-3. Epub 2007 Sep 29.

Abstract

Purpose: The unilateral 6-hydroxydopamine (6-OHDA) lesion rat model is a well-known acute model for Parkinson's disease (PD). Its validity has been supported by invasive histology, behavioral studies and electrophysiology. Here, we have characterized this model in vivo by multitracer imaging [glucose metabolism and dopamine transporter (DAT)] in relation to behavioral and histological parameters.

Methods: Eighteen female adult Wistar rats (eight 6-OHDA-lesioned, ten controls) were investigated using multitracer [(18)F]-fluoro-2-deoxy-D: -glucose (FDG) and [(18)F]-FECT {2'-[(18)F]-fluoroethyl-(1R-2-exo-3-exe)-8-methyl-3-(4-chlorophenyl)-8-azabicyclo(3.2.1)-octane-2-carboxylate} small animal positron emission tomography (PET). Relative glucose metabolism and parametric DAT binding images were anatomically standardized to Paxinos space and analyzed on a voxel-basis using SPM2: , supplemented by a template-based predefined volumes-of-interest approach. Behavior was characterized by the limb-use asymmetry test; dopaminergic innervation was validated by in vitro tyrosine hydroxylase staining.

Results: In the 6-OHDA model, significant glucose hypometabolism is present in the ipsilateral sensory-motor cortex (-6.3%; p = 4 x 10(-6)). DAT binding was severely decreased in the ipsilateral caudate-putamen, nucleus accumbens and substantia nigra (all p < 5 x 10(-9)), as confirmed by the behavioral and histological outcomes. Correlation analysis revealed a positive relationship between the degree of DAT impairment and the change in glucose metabolism in the ipsilateral hippocampus (p = 3 x 10(-5)), while cerebellar glucose metabolism was inversely correlated to the level of DAT impairment (p < 3 x 10(-4)).

Conclusions: In vivo cerebral mapping of 6-OHDA-lesioned rats using [(18)F]-FDG and [(18)F]-FECT small animal PET shows molecular-functional correspondence to the cortico-subcortical network impairments observed in PD patients. This provides a further molecular validation supporting the validity of the 6-OHDA lesion model to mimic multiple aspects of human PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Behavior, Animal / drug effects
  • Cocaine / analogs & derivatives
  • Cocaine / metabolism
  • Disease Models, Animal*
  • Dopamine / metabolism*
  • Dopamine Plasma Membrane Transport Proteins / analysis
  • Dopamine Plasma Membrane Transport Proteins / metabolism
  • Female
  • Fluorodeoxyglucose F18 / metabolism
  • Glucose / metabolism
  • Humans
  • Oxidopamine / toxicity*
  • Parkinson Disease / diagnostic imaging
  • Parkinson Disease / etiology
  • Parkinson Disease / metabolism*
  • Parkinson Disease / pathology
  • Positron-Emission Tomography
  • Rats
  • Rats, Wistar
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • 2'-fluoroethyl 8-methyl-3-(4-chlorophenyl)-8-azabicyclo(3.2.1)octane-2-carboxylate
  • Dopamine Plasma Membrane Transport Proteins
  • Fluorodeoxyglucose F18
  • Oxidopamine
  • Tyrosine 3-Monooxygenase
  • Cocaine
  • Glucose
  • Dopamine